Glaxo warn­ing as it agrees deal for 60m vac­cine doses

The Daily Telegraph - Business - - Front Page - Han­nah Ut­t­ley By

CRU­CIAL vac­ci­na­tion pro­grammes have ground to a halt dur­ing lock­downs around the world, drug maker Glax­oSmithK­line warned as it struck a deal with min­is­ters for 60m doses of its po­ten­tial Covid jab.

In­oc­u­la­tion rates for other dis­eases have slumped as coun­tries fo­cus on fight­ing coro­n­avirus, Glaxo said, adding that its fi­nan­cial per­for­mance will suf­fer this year if take-up does not recover by the third quar­ter as ex­pected.

The FTSE 100 com­pany also signed an agree­ment with the Gov­ern­ment for doses of a coro­n­avirus vac­cine it is de­vel­op­ing with French ri­val Sanofi.

The vac­cine will be pro­vided to the UK if it proves ef­fec­tive when hu­man tri­als be­gin in Septem­ber. Bri­tain has been rac­ing to buy up po­ten­tial Covid jabs so they can be used as soon as test­ing is com­pleted. The UK has now se­cured 250m doses of four dif­fer­ent types of vac­cine, with hopes grow­ing that the first ver­sions will be cleared for use in a mat­ter of months.

Glaxo said: “There re­main no­table risks to busi­ness per­for­mance. The out­come is de­pen­dent on the tim­ing of a re­cov­ery in vac­ci­na­tion rates, par­tic­u­larly in the US. If we were to ex­pe­ri­ence a de­lay in this re­cov­ery we could see a sig­nif­i­cant im­pact in 2020.”

How­ever boss Emma Walm­s­ley noted that vac­ci­na­tions for chil­dren are now back to pre-Covid lev­els.

Newspapers in English

Newspapers from UK

© PressReader. All rights reserved.